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Educational aims
•	 To provide an overview of the gender issues in epilepsy
•	 To highlight the reasons as to why epilepsy affects males and females differently 
•	 To demonstrate precautions to be taken in females on AEDs
•	 To enhance interdisciplinary care in the treatment of epilepsy in both men and women
Abstract
Epilepsy is the third most common chronic neurological condition 
across all ages, affecting around 1% of the population world wide. 
While epidemiological studies do not indicate any differences in the 
incidence of epilepsy in males and females, there may be significant 
differences in the impact and effect the condition may have between 
males and females across all ages. 
These differences may not only be due to possible differences in 
antiepileptic drug (AED) efficacy, AED drug-drug interactions due to 
hormonal differences, and possible teratogenetic effects in women 
of child bearing age, but also differences in the social impact of the 
condition.  These issues challenge both the woman with epilepsy, and 
the various health care professionals involved in her care.
Introduction
Epilepsy is the third most common 
neurological condition, and annual incidence 
is estimated as 43 cases per 100,000 of the 
population worldwide. It is characterized 
by occurrence of unprovoked seizures 
accompanied by complex symptoms, due 
to disorders of brain function.1 Despite 
extensive research on epilepsy and seizure 
mechanisms, treatment is still limited to 
symptomatic rather than mechanism-oriented 
approaches. In fact, the emerging genetic 
basis of some of the epilepsies, indicate that 
epilepsy will eventually be recognised as 
several different conditions.
There is now also an increased 
understanding of gender differences in the 
epidemiology of epilepsy and of specific 
epilepsy syndromes.  Various published 
studies indicate that females have a 
marginally lower incidence of epilepsy 
and unprovoked seizures than males. 
This difference is usually attributed to a 
greater exposure to risk factors for lesional 
epilepsy and acute symptomatic seizures in 
males. Males also have a higher incidence 
of status epilepticus, sudden unexpected 
death in epilepsy (SUDEP), prognosis, and 
mortality. However, idiopathic generalized 
epilepsies (IGEs) are more common among 
female.2  These differences may be due to 
the influence of sex hormones on seizures 
and epilepsy, as well as changes in the 
endocrine system and levels of sex hormones 
by epileptiform activity.3 
Conversely, seizures may be sensitive 
to changes in sex hormone levels, which 
in turn may affect the seizure-induced 
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neuronal damage. Animal studies indicate 
that the effects of reproductive hormones on 
neuronal excitability, seizures, and seizure-
induced damage are complex because of the 
multifaceted action of steroid hormones. 
These can induce genomic effects involving 
modulation of multiple genes by their up- or 
down-regulation and rapid non-genomic 
effects by activation of membrane orphan 
G-protein coupled receptors, specific 
membrane hormone receptors, or by direct 
binding to neurotransmitter receptors.4 
Choice of AEDs and sexual development
Relative to males, females with epilepsy 
face unique challenges. Epilepsy affects 
sexual development, menstrual cycle, can 
influence choice of contraception, and may 
affect pregnancy outcomes. These factors will 
have an impact of the choice of an AED in 
patients with epilepsy, due to differences 
in the efficacy and safety of each drug, 
and also on the patient’s acceptability of 
the drug.1  Although most pregnancies 
are uneventful in women with epilepsy, 
preconception advice should be given to all 
women with epilepsy who are considering 
pregnancy, such as folic acid and vitamin K 
supplements. The lowest effective dose of the 
most appropriate AED should be used. A study 
carried out in France among epileptologists 
indicated a consensus for the selection 
of AEDs, mainly based on the epilepsy 
syndrome and gender. Sodium valproate 
and lamotrigine were found to be the two 
drugs of choice for generalized epilepsies, 
with lamotrigine often preferred for women 
of childbearing age. Carbamazepine was first 
line AEDs in men with partial epilepsy, with 
lamotrigine preferred in females.5  However, 
other studies found that the combination 
of valproate and lamotrigine is particularly 
teratogenic. Moreover, lamotrigine was found 
to cross into breast milk and thus could 
accumulate in the child.6 
AEDs which are nonenzyme-inducing, 
such as valproate, benzodiazepines and 
levetiracetam, do not interact with oral 
contraceptives (OCs). However, inducing 
AEDs, such as phenytoin, barbiturates, 
carbamazepine, topiramate, will affect the 
efficacy of OCs.3 In another study looking 
at a cohort of 212 females, depression, 
female gender, symptomatic etiology, 
younger seizure onset age, ≥2 seizures, and 
history of febrile seizures were found to 
be associated with a higher adverse effect 
profile. Menopause was also found to affect 
seizure frequency and type and women with 
epilepsy. In addition, women on AEDs were 
found to be at increased risk of fractures, 
osteoporosis, and osteomalacia.7 
Co-morbidities in epilepsy
Co-morbidities in epilepsy are very common.  
These can include  behavioural changes 
in children, and anxiety and depression 
in adults.  Wilner et al., (2014) assessed 
the prevalence of the most common co-
morbidities in 6621 women and men 
with epilepsy (52% women, 48% men).8 
More women (50%) than men (43%) with 
epilepsy were found to have comorbidities 
(p<0.05). The most common co-morbidities 
found in women were psychiatric diagnosis 
(16%), hypertension (12%), asthma (11%), 
hyperlipidemia (11%), headache (7%), 
diabetes (6%), urinary tract infection (5%), 
hypothyroidism (5%), anemia (5%), and 
migraine (4%). For men, these co-morbidities 
were found to be psychiatric diagnosis (15%), 
hyperlipidemia (12%), hypertension (12%), 
asthma (8%), diabetes (5%), headache 
(4%), cancer (4%), coronary artery disease 
(3%), anemia (3%), and gastroesophageal 
reflux disease (3%). Psychiatric diagnosis 
was the only comorbidity among the top five 
comorbidities across all age groups in both 
men and women. 
AEDs are often blamed for these co-
morbidities, although they may not always 
be at fault. Indeed, it is crucial for patients 
that their care should include a wider 
perspective than merely reduction in seizure 
frequency, but also consider the broader 
aspects of epilepsy and its effects on quality 
of life.
Epilepsy surgery
Epilepsy surgery can also be perceived 
differently by males and females. In a study 
among a cohort of 389 men and women 
who underwent epilepsy surgery, both 
genders highlighted the possible impact on 
driving and memory, as the most important 
presurgical concerns. However, females 
fatigue and pregnancy as major concerns, 
while males rated driving, physical activity 
limitations, and economic worries as more 
important (p  ≤ 0.05).9 
Quality of life
Despite advances in the understanding and 
effective management of epilepsy (more than 
70% of persons with epilepsy have their 
seizures controlled with AEDs), there is often 
a mismatch between visible disability and 
perceived disability in these persons. This 
is because for many patients, while their 
seizures are controlled and they appear to be 
perfectly well and healthy, epilepsy can have 
a huge impact on the social, psychological, 
and physical health due perceived and real 
stigma as well as due to the side effects 
of AEDs.7 Moreover, persons with refractory 
epilepsy face many challenges such as 
the unpredictability of seizures, problems 
with employment, learning and cognitive 
difficulties, physical activity limitations, and 
pregnancy concerns. In addition, epilepsy 
can impact on certain aspects of education 
and employment, mood changes, lifestyle 
choices.8 
Patient-reported outcome measures are 
increasingly being used in assessing quality 
of life in persons with epilepsy. Using the 
World Health Organization Quality-of-Life 
Questionnaire - Brief (WHOQOL-Bref), the 
Health Related Quality of Life (HRQoL) in a 
cohort of men with epilepsy, was compared 
to seven other groups with chronic diseases. 
Multiple linear regression showed that 
mood was the most important independent 
predictor of the WHOQOL-Bref score.10  Yet, 
various other studies have indicated that 
factors influencing quality of life in females 
are far more complex. While choice of 
treatment should be based on the individual 
patient’s specific clinical characteristics, 
selection of AEDs and other treatment should 
also consider the patient’s particular lifestyle 
and priorities, which may be far more 
heterogenous in women.11 
How can pharmacists help?
Various studies have shown that the best 
approach in caring for women with epilepsy 
is a multi disciplinary one.1 In a chronic 
condition, such as epilepsy, pharmacists can 
serve an important function in the health 
care of patients with this chronic disease. 
In a study among 175 pharmacists in the 
US, which used the Knowledge of Women’s 
Issues and Epilepsy II (KOWIE-II) tool, 
nearly 75% of pharmacists scored correctly 
for the statement inquiring about the drug 
interaction between enzyme-inducing AEDs 
and contraceptives.12 Slightly less knew about 
AED-induced bone loss. Almost one-third 
of the respondents answered incorrectly 
when asked about the frequency of sexual 
dysfunction in women with epilepsy, though 
an even higher percentage chose “don’t 
know.” Most of the pharmacists (69.1%) 
stated “don’t know” when asked about 
the relationship between hormones and 
seizure control. More than 70% correctly 
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answered four of six pregnancy-related 
statements (use of folic acid=77.0%, healthy 
babies=82.9%, continued AED adherence 
during pregnancy=86.8%, choice of AED 
during pregnancy=71.1%). Fewer pharmacists 
knew about vitamin K supplementation 
(57.9%), and even fewer answered the 
question on breastfeeding correctly (33.6%).  
The pharmacist has a key role in ensuring 
continuity of care in persons with epilepsy 
especially in females. This can only be 
addressed through continuing professional 
education.
Conclusions
As has been seen from this brief review, 
differing effects of sex hormones can lead 
to significant differences between men and 
women in prognosis, treatment and social 
impact of persons with epilepsy. These 
differences could range from the incidence 
of various types of seizures, decreased 
fertility rates in females, pregnancy-related 
complications, and social impact and 
quality of life. Gender also has an impact 
on the treatment of epilepsy, selection of 
antiepileptic drugs (AEDs) and incidence of 
co-morbidities. 
To date, the focus on gender issues in 
epilepsy has been mostly on females, with few 
studies being carried out in males. Indeed, 
guidelines for the management of women 
with epilepsy have been available for many 
years.13. Yet, despite these guidelines, studies 
have indicated that their implementation 
needs to be improved, with much more 
information being given to patients in an 
interdisciplinary care approach.  Pharmacists 
can be instrumental in this regard.
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Key points
•	 Differences between men and women in epilepsy may be due to the influence of 
sex hormones on seizures and epilepsy, as well as due to changes in the endocrine 
system and levels of sex hormones by epileptiform activity. 
•	 Epilepsy affects sexual development, menstrual cycle, can influence choice of 
contraception, and may affect pregnancy outcomes in females.
•	 Common co-morbidities between men and women differ.
•	 The choice of AED treatment should also consider the patient’s particular lifestyle 
and priorities which may be far more heterogenous in females.
•	 Pharmacists can be instrumental in imparting information to men and women with 
epilepsy in an interdisciplinary care approach.
